Gerson Lehrman Group - Intelligently Connecting Institutions and Expertise.

Study Group: Generic Drug Economic Experts

Council Members in this Study Group: 767

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Contact Gerson Lehrman Group to survey or consult with members of this Study Group

Leading institutions connect with members of this Study Group through GLG

Leading Experts in this Study Group

Hany Salama, Vice President, Commercial Operations, NEOSTRATA COMPANY, INC.Hany Salama

Vice President, Commercial Operations
NEOSTRATA COMPANY, INC.
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Hany Salama, ME, MBA, CPM, is the Vice President, Commercial Operations at The NeoStrata Company. He has global responsibilities for commercial planning, supply chain, and manufacturing operations for all clinical and marketed products. Mr. Salama is also responsible for all new commercial productlaunches...

2 recent news post(s)
Louis Rocco

System Director of Purchasing
HALLMARK HEALTH SYSTEM, INC.
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Louis Rocco is the System Director of Purchasing at Hallmark Health System, in Massachusetts. He has over 25 years of experience in purchasing and has negotiation, analytical, reporting and communication skills in inventory, distribution, purchasing, mailroom, reimbursement and accounts payable background....

1 recent news post(s)
Adam Fein, PhD, Founder & President, PEMBROKE CONSULTING INCAdam Fein, PhD

Founder & President
PEMBROKE CONSULTING INC
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Adam Fein, PhD, is the Founder and President of Pembroke Consulting, Inc., a Philadelphia-based management advisory and business research firm. Dr. Fein is one of the country’s foremost experts on pharmacy economics and the pharmaceutical supply chain. He provides strategic advisory services to a diverse...

165 recent news post(s)
Stephen Bent, Partner, FOLEY & LARDNER LLPStephen Bent

Partner
FOLEY & LARDNER LLP
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Stephen A. Bent is Partner and former co-leader of the Life Sciences Industry Team at Foley & Lardner in Washington, DC. He is also a member of the Biotechnology & Pharmaceutical Practice Group and the Health Care and Nanotechnology Industry Teams. Mr. Bent specializes on the legal issues associated...

Michael McNeely

Principal
Law Offices of Michael D. McNeely
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Michael McNeely is in private practice in Washington, DC, where he provides antitrust counseling and representation. Mr. McNeely consults on the antitrust and antitrust agency aspects of mergers, generic drug approvals, telecommunications, patents, standard setting, and other topics. He also represents...

Eric Gruff, PhD MBA, Principal, E4 ConsultingEric Gruff, PhD MBA

Principal
E4 Consulting
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Eric Gruff, PhD, MBA, BS, is Founder of E4 Consulting, which specializes in pharmaceutical development, regulatory affairs, and project and portfolio management. Dr. Gruff has over 17 years of experience in the pharmaceutical and biotech sector, including leadership roles at Pfizer, Agouron Pharmaceuticals,...

11 recent news post(s)
Alan Patterson, MD

Obstetrician and Gynecologist
ALAN B PATTERSON MD, PA
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Alan Patterson, MD, is an Obstetrician and Gynecologist at Alan B Patterson MD, a private practice in Florida, since May 1991. Dr. Patterson was on the teaching staff at Methodist Hospital, Indianapolis, where he wrote many protocols for the residency program. In the past few years, Dr. Patterson has...

1 recent news post(s)
Evan Siegel, MPhil, PhD

Adjunct Professor
THE UNIVERSITY OF QUEENSLAND
What is a GLG Leader?|GLG Leaders are a separate tier of Council Members with a Council Rank in the top 5%. These GLG Member Program participants are eligible for ongoing, in-depth consultative relationships with GLG clients.

Evan Siegel, M Phil, Ph D, is the President and Chief Executive Officer of Ground Zero Pharmaceuticals, a regulatory affairs and product development consulting firm in California, since June 1999. Dr. Siegel is also an Adjunct Professor at the University of Queensland, since November 2006. He provides...

8 recent news post(s)
1 recent event(s)

View all Leading Experts in this Study Group

GLG NewsSM Analyses by this Study Group's Leading Experts (?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.

A triple combination for H1N1: good in principle

October 30, 2009

John Ansell, MBA, Director, John Ansell Consultancy

Triple-combo Drug Shows Promise Against Antiviral Resistant H1N1 | www.medicalnewstoday.com

The principle behind Adamas’s triple combination development for influenza is a good one. There is clearly a need for improved treatments, as the latest wave of swine flu is now showing. Oseltamivir (Tamiflu) and ribavirin are reasonable drugs to select but the third component, amantadine, may prove...

Express Scripts feeling Growing Pains

October 29, 2009

GLG Expert Contributor

Express Scripts to Close NextRx Deal in 4Q | quicktake.morningstar.com

On 11/04/09 TriCare, the health insurance plan for the US Military and its families are being moved to a new pharmacy benefit administered by Express Scripts. Despite assurances of transparency and no change in pharmacies, thousands of beneficiaries are being directed by Express Scripts to a single...

Turn around signs seen in healthcare !!! Dr. Reddy's & Ranbaxy beat the trend!!!

October 27, 2009

GLG Expert Contributor

UPDATE 1-New generics help India Dr Reddy's beat Q2 f'cast | in.reuters.com

After 4 - 5 quaters of negative growth, cost cuts, product rationalization etc... we have some good news from bell weather stocks of Indian pharma market.Dr. Reddy's & Ranbaxy both are reporting profits after of year of dismal performance.This is also a sign of overall market changing its down ward...

Particle Beam Radiation Therapy (PBRT) life saving technology but who will pay?

October 22, 2009

GLG Expert Contributor

Particle Beam Radiation Therapy published by AHRQ | effectivehealthcare.ahrq.gov

PBRT is an exciting technology that has emerged as a life saver for children and many adults with head/neck , eye and other difficult to treat cancers. Proton Centers require massive investments from $100-250 million. Payor groups from Medicare to commercial plans are faced with whether to pay forthis...

GSK's new venture into Duchenne's makes sense

October 14, 2009

John Ansell, MBA, Director, John Ansell Consultancy

GlaxoSmithKline and Prosensa form alliance to fight Duchenne Muscular Dystrophy | www.pipelinereview.com

GSK's latest deal on Duchenne's muscular dystrophy with the Dutch company Prosena is a further indication of the former's interest in diversifying out of the more obvious, major areas of medicine.This can make sense: such "esoteric" indications areas are less well understood, there is less competition...

View All GLG News by members of this Study Group

Members in this Study Group include these company types:

  • Pharmaceuticals Manufacturer
  • Consultancy, Pharma-Focused
  • Academic Medical Center/Hospital or Clinic
  • Consultancy, Healthcare-Focused
  • Pharmacy or Drug Store, Chain
  • Office Based Private Practice or Clinic
  • Pharmacy or Drug Store, Independent/Local
  • Individual/Small Consultancy

Members in this Study Group often have these job titles:

  • Director
  • President
  • Pharmacist - RPh/PharmD
  • Owner
  • Physician - Attending Physician
  • Chief Executive Officer
  • Principal
  • Consultant
  • Manager
  • Operations Executive

Related Study Groups

Study Group Name No. Members
Pharmacists (US) 2079
Experts on Generic Pharmaceuticals: Pharmacists 107
Economic Experts on Managed Care 716
Formulary Design Experts 252
Managed Care Experts 670
Medicare Experts 495
Generic Pharmaceuticals Regulation Experts: Healthcare Consultants 45

GLG Live Meetings with this Study Group's Leading Experts (?)

Upcoming Seminars

Leading Experts in Generic Drug Economic Experts Study Group have not participated in any upcoming seminars.

View All GLG Live Meetings in Healthcare

GLG Webcasts

Leading Experts in Generic Drug Economic Experts have not participated in any GLG webcasts.

View All GLG Webcasts in Healthcare